Over half of trial patients in EU marketing submissions are from third countries
This article was originally published in SRA
Some 61% of the patients who took part in the pivotal clinical trials used to support marketing authorisation applications submitted to the European Medicines Agency between 2005 and 2009 came from third countries, a report by the agency has revealed1. In addition, since 1997, good clinical practice inspections have been requested for only 228 of the 44,034 investigator sites counted as part of the pivotal trials in these MAAs, illustrating the very small sample of sites that are, or can be, inspected.
You may also be interested in...
A number of new products have been submitted for review at the European Medicines Agency. While marketing authorization applications from ViiV Healthcare and BioMarin Pharmaceutical are being fast-tracked, a submission from Incyte is not.
Medtronic Wins In England’s NICE Decision On Implantable Monitors For Stroke Patients; Biotronik And Abbott Lose
UK health technology assessment body NICE says that Medtronic’s Reveal LINQ, which transmits data remotely to doctors, is likely to be a cost-effective use of National Health Service resources.
Using the QALY is expected to help the Danish Medicines Council make its decisions on the cost effectiveness of drugs more transparent, but it will also extend the time the council takes to make a recommendation.